The single most repeated piece of advice on every peptide board, phrased a hundred ways but always the same underneath: starting multiple agents at once means that when you get effects — or adverse effects — you will have no idea which one caused them.
It is repeated because it is ignored. The vial order arrives with three compounds in it, everything gets reconstituted the same evening, and week six brings either a great result or a strange one, and no way to attribute it. The information was destroyed at the moment of the first injection, and no amount of careful logging afterwards recovers it.
Common peptide stacks covers what goes together and why the mechanisms complement. This article is about how to introduce them so the answer means something. A good stack, started badly, is indistinguishable from a bad stack.
Introduce one variable at a time
The rule is simple and the discipline is not: one change per interval, and nothing else changes.
A “variable” is broader than most people count. Adding a peptide is a variable. So is a dose change, a frequency change, a switch of vendor, a change of injection site strategy, and — this is the one that catches everyone — starting a new training block or a new diet in the same week. If two things changed, you have one data point about a combination, not two data points about two compounds.
Set a baseline first
Before the first injection, run two weeks of nothing. Log the same two or three outcomes you plan to track later, at the same times, under the same conditions.
This feels like wasted time. It is the most valuable part of the protocol, for a boring reason: you do not know what your normal variance looks like. Sleep quality, joint pain, morning weight, mood — all of them swing considerably week to week with no intervention at all. Without a baseline, week three’s good sleep looks like a signal. With a baseline, you might see that you get a run of good sleep roughly every fortnight regardless, and the compound has to beat that to count.
A baseline also gives you the honest starting number. Memory of “before” reconstructs itself to fit the story of “after” — reliably, in everyone, including people who know it happens.
The washout is set by half-life, not by the calendar
“Wait a week between compounds” is folk advice that happens to be right about half the time. The right interval is a function of the half-life of the compound you’re clearing, and peptide half-lives span four orders of magnitude.
The working rule is roughly five half-lives to be functionally clear of a compound. For BPC-157, that’s about a day — a week is generous. For semaglutide, five half-lives is over a month, which is why “I waited a week before adding the next thing” is meaningless there: you added the second compound into a background of near-full first compound. That’s not sequential introduction, that’s a stack with extra steps.
Long-acting compounds also accumulate, so the relevant question isn’t only when the last dose clears but where you are on the accumulation curve. Look up what you are actually running on the half-life chart before you pick an interval. If the number is in days, the washout is in weeks.
- 1
Weeks 1-2 — baseline
No compounds. Log the same 2-3 outcomes daily. This is what your normal noise looks like.
- 2
Weeks 3-6 — compound A alone
One peptide, one dose, everything else held constant. Long enough to see past week-to-week swing.
- 3
Week 7 — read it
Compare against baseline, not against memory. Decide whether A stays before A becomes background.
- 4
Weeks 8+ — add compound B
Only now. Anything new from here is attributable to B, because A is a known quantity.
Record less than you think
The instinct is to log everything: forty fields, a mood score, HRV, three biomarkers, sleep stages, a free-text note. That log gets abandoned by week two, and if it doesn’t, it produces a different problem — enough measures that something will look like it moved by chance alone.
Log this:
- Dose (mcg or mg, not “one click” or “the usual”)
- Time of injection
- Site
- Two or three outcomes, chosen before you start, that you actually care about
That’s it. Decide the outcomes in advance and write them down, because choosing them afterwards is how you end up crediting a compound for the one thing out of twenty that happened to move. If the reason you bought a peptide was tendon pain, then tendon pain is the outcome — not the general sense that things are going well.
Rate outcomes on something coarse. A 0-10 pain scale beats a paragraph, because you can plot it and you’ll actually fill it in.
The confounders that wreck peptide self-experiments
These are not hypotheticals. They are how most self-experiments fail:
- Starting in January. New year, new protocol — and new training, new diet, new sleep schedule, and a fresh burst of motivation. Everything improves. Nothing is attributable. If you must start alongside a life change, start the compound six weeks after the life change, not with it.
- Changing training at the same time. The classic on healing peptides. You start BPC-157 and, feeling optimistic, also back off the movement that was aggravating the tendon. The tendon improves. Which one did it?
- Changing diet at the same time. Especially on metabolic compounds, where the compound changes appetite, which changes diet, which changes the outcome — a real effect, but not the one you think you’re measuring.
- Seasonal mood. Mood, energy and sleep have a large seasonal component. A nootropic peptide started in February looks miraculous by May.
Regression to the mean
This one deserves its own heading because it explains more false positives than anything else on the list.
People start peptides when things are bad. That’s the trigger — the shoulder is at its worst, sleep has been terrible for a month, the plateau has been going for six weeks. And “at its worst” is, statistically, the moment most likely to be followed by improvement, because extremes are extremes. The shoulder was going to settle. Sleep was going to normalise. It would have happened with no injection at all.
You cannot eliminate this, but you can account for it. A baseline period helps, because if the bad patch is already resolving during your two baseline weeks, you’ll see the slope. Starting when things are average rather than at rock bottom helps more, though it takes discipline nobody has when the shoulder hurts. And treating a single dramatic improvement in week one with suspicion helps — real effects with a mechanistic basis usually build; a rebound that was already coming tends to arrive fast and get credited to whatever you did most recently.
Placebo, taken seriously
Placebo is not “it’s all in your head”, and dismissing it as gullibility misses what’s actually going on.
You bought the vial. You reconstituted it carefully. You are injecting yourself several times a week and paying attention to your body in a way you were not two weeks ago. That’s an expensive, effortful, high-attention ritual, and it reliably shifts subjective outcomes — pain, sleep quality, mood, energy — by a real, measurable amount. In trials, placebo arms on pain endpoints routinely post improvements that would look impressive in an anecdote. Those people are not lying and neither are you.
Two practical consequences. First, subjective endpoints need a bigger effect to convince you than objective ones. A 1-point move on a 10-point pain scale in the first fortnight is inside placebo range. Grip strength, a load you can lift, morning weight, a blood marker — these are harder to wish into existence. Prefer them where you can.
Second, placebo doesn’t fade evenly. It’s largest at the start, which is exactly when people decide whether a compound “works”. Week eight is a more honest read than week one, and a compound still ahead of baseline at week eight after the novelty has worn off has told you something.
None of this means the effect isn’t worth having — if your shoulder hurts less, your shoulder hurts less. It means don’t spend €400 a month on a compound to buy an effect the ritual was providing.
Frequently Asked Questions
How long should I run one peptide before adding a second?
Four weeks alone is a reasonable default for most compounds — long enough to see past week-to-week noise and past the front-loaded part of the placebo response. Two weeks is often too short to distinguish an effect from normal variance. For long-half-life compounds that accumulate for weeks before reaching steady state, wait until the level has actually plateaued before judging anything.
How long is a washout between peptides?
Roughly five half-lives to be functionally clear, which means the answer is entirely compound-dependent. A week is generous for BPC-157 (hours-long half-life) and close to useless for semaglutide (about a week), where five half-lives is over a month. Check the compound on our half-life chart rather than defaulting to a week.
Do I really need a baseline period?
It’s the part people skip and the part that does the most work. Without two weeks of before-data you have no idea what your normal variance looks like, so you cannot tell whether week three’s improvement is a signal or an ordinary swing — and memory of how things were before reliably reshapes itself to fit what happened after.
What should I actually track?
Dose, time, site, and two or three outcomes chosen before you start. Not forty fields — long logs get abandoned, and tracking many measures guarantees that one of them moves by chance. Pick the outcome that made you buy the compound, prefer objective measures where they exist, and use a coarse scale you’ll fill in every day.
Is it ever fine to start two peptides together?
Yes — when you have accepted in advance that you’re evaluating the combination as a single unit and won’t be able to attribute anything to either component. That’s a legitimate choice if the pairing is well established and you only care whether the stack works. It stops being fine the moment something goes wrong and you need to know which one to drop.
Related reading
- Common Peptide Stacks — what to combine, once you know how to introduce it
- Peptide Half-Life Explained — the number that sets your washout
- Pre-Mixed Blends vs Separate Vials — why a blend makes attribution structurally impossible
- Beginner’s Guide to Peptide Research — the groundwork before any of this